OsmanKostekMD· @OncologyMarwarD · X·· 2 days agoScore70
Body · original
🚨 ESMO 2026 | AMPLIFY-7P
KRAS vaccine camupepimut in resected PDAC:
❌ Primary DFS endpoint not met (HR 0.85; p=0.53).
✅ ctDNA−: HR 0.51
✅ ctDNA+: HR 0.57
✅ Strong KRAS-specific T-cell response linked to better DFS (HR 0.22).
🎯 Promising signals.. #ESMO26
64 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683Pmatched by NSCLC, metastatic
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.orgSource: OsmanKostekMD · x.com